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Abstract An 8-year-old patient with genetically confirmed
chronic infantile neurological cutaneous and articular syndrome
was treated with interleukin-1 receptor antagonist, anakinra. She
initially presented with recurrent episodes of fever, rash, chronic
fatigue, frequent headaches, ocular involvement (corneal infil-
trate and papillary edema), and permanent increased biologic
inflammatory markers. Following treatment with anakinra, all
symptoms and inflammation resolved. Ophthalmologic signs
normalized. This ophthalmologic description (optic nerve and
cornea) has never been illustrated, even if ocular affections are
classic in the cryopyrin-associated periodic syndromes.
Introduction
Cryopyrin-associated periodic syndromes (CAPS) have
been proposed to describe cryopyrin-related diseases with
heterogenous phenotype severity. The mildest condition is
the familial cold auto-inflammatory syndrome, patients
with Muckle–Wells syndrome have an intermediate pheno-
type, the chronic infantile neurological cutaneous and
articular syndrome (CINCA) also known as neonatal onset
multisystem inflammatory disease (NOMID) is the most
severe disease in this spectrum [1, 2]. The patients are
presenting urticaria and life-like skin rash from early in life,
variable articular involvement (arthralgia/arthritis is asso-
ciated in 30% of cases with hypertrophic arthropathies),
chronic aseptic meningitis, and neurosensorial involvement
associated with biologic markers of neutrophil-driven
inflammation. Broad ophthalmologic abnormalities have
been described in CINCA/NOMID. An international col-
laborative study based on a questionnaire including 31
patients described the optic disc changes as the most
common feature (83%), including optic disc edema,
pseudopapilledema, and optic atrophy. Anterior segment
manifestations varying from mild to severe (42%); chronic
anterior uveitis (55%) [3]. CAPS are all caused by
dominantly inherited or de novo mutations in CIAS1,a
gene that encode for NLRP3 (also known as cryopyrin/
NALP3/PYPAF1) [4, 5]. NLRP3 is a component of
interleukin-1 (IL-1) inflammasome that regulates IL-1β
production, a strong pro-inflammatory cytokine. Mutations
of CIAS1 associated with CAPS result in a gain-of-function
effect. Thanks to substantial advances in understanding
genetic basis and mechanisms of these disorders, new
therapeutics targeting the IL-1 pathway could be proposed as
recombinant nonglycosylated homolog of human interleukin-1
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DOI 10.1007/s12348-010-0018-2receptor antagonist (IL-1Ra), anakinra that competitively
inhibits binding of IL-1α and IL-1β to IL-1 receptor. Previous
studies showed remarkable efficacy of anakinra in patients
suffering from CIAS1-associated diseases [6].
In the presenting case of CINCA/NOMID successfully
treated by anakinra, we report and document normalization
of ophthalmologic involvement undertreatment.
Case report
The patient, an 8-year-old Caucasian girl, was referred to
the Pediatric Immuno-hematology and Rheumatology
Department for diagnosis and treatment of CINCA/NOMID
syndrome. Diagnosis was suspected based on medical
history of the child. She was born preterm at 30.5 weeks
of gestational age with normal weight and height for age
(2,010 g and 41.5 cm). She was issued from a twin
pregnancy. Because the twin child was diagnosed with
trisomy 13, in utero reduction was performed. Prematurity
might be related to this procedure rather than to the disease.
She presented with daily urticaria-like rash associated with
fever since 1 week of age. Arthralgia and transient haunch
swelling revealed with nonsteroidal anti-inflammatory
drugs were reported at the age of 3 years. Since the age of
two, she also complained of recurrent episodes of headaches.
Diagnosis of CAPS was genetically confirmed (after the
parents provided written informed consent according to the
recommendations of the Declaration of Helsinki) and
revealed a previously reported mutation, D303N, in the
CIAS1 gene. Extensive baseline evaluation was performed
before starting treatment with IL1-Ra, anakinra. Clinical
examination confirmed the rash. Height and weight were
1.3 m and 24.8 kg, respectively. Biologic inflammatory
markers were increased [C-reactive protein 40 mg/dl
(normal <5)], white blood cell count 11,800 cells/mm
3,
and neutrophil count 7,860 cells/mm
3). Bone X-Ray con-
firmed the absence of arthropathy. Lumbar puncture was
performed and cerebrospinal fluid (CSF) examination
revealed pleocytosis (25 cells/μl with 90% neutrophils),
increased proteinorachia (protein level 0.71 mg/l), and high
open pressure (21 H20 cm). Brain MRI (with FLAIR
imaging and contrast injection) was normal (absence of
abnormalities of small vessels of the basal ganglia and
periventricular white matter lesions). Cognitive performances
were normal. Audiographic examination showed mild
bilateral sensorineural deafness (−20 dB). Vision was
preserved in both eyes (20/25 Snellen visual acuity). The
Goldmann visual field illustrated a mild blind spot enlarge-
ment. Slit lamp biomicroscopy revealed bilateral anterior,
nummular, stromal keratitis, and absence of anterior uveitis
(Fig. 1). On fundus examination and photographs of both
eyes, we observed a bilateral papilledema without vitritis.
Diagnosis of CINCA/NOMID was performed.
The patient did not receive any steroids or immunosup-
pressive treatment before initiation of anakinra treatment.
Follow-up period is 30 months; initial dose of 2 mg/kg/day
in subcutaneous injection has been maintained. All symp-
toms related to the diseases (rash, headaches, arthralgia, and
chronic fatigue) ceased durably in few days. Biologic
inflammatory markers [C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR)], white blood cells, and
neutrophil numerations rapidly decrease 1 month after
initiation of the anti-IL-1 treatment. Inflammation markers
rates were normalized and stabilized during the follow-up
(Fig. 2). The velocity of growth was restarted and the
height and weight increased progressively during the
treatment. Audiogram remained stable overtime.
Fig. 1 Baseline biomicroscopic examination. Anterior segment
photograph illustrates anterior stromal infiltrations of the cornea, these
were well defined and corneal epithelium is respected (fluorescein test
was negative). The anterior chamber was calm (absence of tyndall and
synechiae)
Fig. 2 Change in level of C-reactive protein (CRP) with anakinra
treatment after 30 months of follow-up. Vertical discontinued line
indicated the introduction time of anakinra. CRP rapidly decreases
1 month after initiation of the IL-1Ra treatment. CRP was normalized
and stabilized during the follow-up
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infiltrates disappeared. On fundus examination and photo-
graphs of both eyes, we observed a pale optic disc
corresponding to the resolution of the papilledema
(Fig. 3). The campimetry was not modified by the treatment
and the blind spot enlargement was stable between the
different exams. No adverse events and severe infection
occurred. Treatment was well tolerated.
Discussion
Here we report a case of CINCA/NOMID with chronic
inflammation and neurosensorial involvement but without
hypertrophic arthropathy successfully treated with IL-1Ra,
anakinra. The recombinant form of the naturally occurring
IL-1Ra is called anakinra (rmetHuIL-1Ra), and differs from
the native human protein that is not glycosylated and has an
additional N-terminal methionine [7]. Anakinra competi-
tively inhibits binding of large number of IL-1 receptors, as
these receptors are expressed on all cells except red blood
cells. IL-1 is a major inflammatory mediator and induces
fever, anorexia, hypotension, leucopenia, and thrombocy-
topenia. IL-1 stimulates production of IL-6, fibrinogen, and
complement components. IL-1 also stimulates the hypo-
thalamic–pituitary–adrenal axis [8] and promotes Th17
differentiation. Th17 is involved in autoimmunity and
Th17 cells are pivotal in autoimmune uveitis [9]. Eye
involvement in our patient was characterized by papillary
edema and cornea infiltrate. Ophthalmologic involvement
in CAPS are pleiotropic as episclera, anterior chamber,
vitreous, and optic disc can be affected [10, 11]. To the best
of our knowledge, corneal infiltrates were not previously
reported. The explanation proposed regarding reversal
nummular infiltrates included [1] cellular inflammatory
infiltration in the stroma or [2] reversal amyloid deposits.
The first hypothesis seems to be more rational because in
this case, systemic amyloidosis was not present. Papille-
dema is related to chronic intracranial hypertension due to
chronic CSF inflammation. Anakinra was dramatically
efficient to treat systemic inflammation, articular pain and
recurrent headaches were also relieved. Ophthalmologic
improvement was also remarkable as shown in Fig. 3:
papilledema resolved in 6 months as corneal infiltrates.
Unfortunately, visual field does not improve because of
papilledema duration before anti-IL-1Ra treatment and
alteration of the optic nerve fibers.
The auto fluorescence fundus photographs did not show
hyper signal resulting in auto fluorescent material accumu-
lation (not shown). Unfortunately, visual field does not
Fig. 3 Funduscopy follow-up
after anakinra introduction. a
Baseline ophthalmologic exami-
nation: color fundus photograph
shows bilateral papilledema
without vitritis or vasculitis in
the right eye (A1) and in the left
eye (A2). b Twelve months
follow-up ophthalmologic
examination after anakinra has
been introduced. Modifications
of the cornea were resolute
ad integrum (not shown).
Funduscopy show bilateral pale
optic disc without edema, (B1)
right eye and (B2) left eye
J Ophthal Inflamm Infect (2011) 1:133–136 135improve because of papilledema duration and alteration of
the optic nerve fibers.
We confirmed improvement in fundus examination and
regulation of CSF white cell counts with IL-1 receptor
antagonism in the treatment of auto-inflammatory conditions.
Also, we suggest, early in the course of the disease, the use of
IL-1 receptor antagonist as a therapeutic option to chronic
papilledema in order to prevent irreversible consequence of
chronicexcessiveintracranialpressureandfinalopticatrophy.
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